简介：Immunotherapyhasbecomeakeystrategyforcancertreatment,andtwoimmunecheckpoints,namely,programmedcelldeath1(PD-1)anditsligand(PD-L1),haverecentlyemergedasimportanttargets.TheinteractionblockadeofPD-1andPD-L1demonstratedpromisingactivityandantitumorefficacyinearlyphaseclinicaltrialsforadvancedsolidtumorssuchasnon-smallcelllungcancer(NSCLC).ManycelltypesinmultipletissuesexpressPD-L1aswellasseveraltumortypes,therebysuggestingthattheligandmayplayimportantrolesininhibitingimmuneresponsesthroughoutthebody.Therefore,PD-L1isacriticalimmunomodulatingcomponentwithinthelungmicroenvironment,butthecorrelationbetweenPD-L1expressionandprognosisiscontroversial.MoreevidenceisrequiredtosupporttheuseofPD-L1asapotentialpredictivebiomarker.ClinicaltrialshavemeasuredPD-L1intumortissuesbyimmunohistochemistry(IHC)withdifferentantibodies,buttheassessmentofPD-L1isnotyetstandardized.Somecommercialantibodieslackspecificityandtheirreproducibilityhasnotbeenfullyevaluated.FurtherstudiesarerequiredtoclarifytheoptimalIHCassayaswellastopredictandmonitortheimmuneresponsesofthePD-1/PD-L1pathway.

简介：Inthispaperourstudiesaboutthesequentialtestingprogramforpredictingandidentificatingcarcinogens,sequentialdiscriminantmethodandcost-effectivenessanalysisaresummarized.Theanalysisofourdatabaseofcarcinogenicltyandgenotoxicityofchemicalsdemonstratestheuncertainty.ofshort-termtests(STTs)topredictcarcinogensandtheresultsofmostroutineSTTsarestatisticallydependent.WerecommendthesequentialtestingprogramcombiningSTTsandcarclnogenicityassay,theoptimalSTTbatteries,therulesofthesequentialdiscriminationandthepreferalchoicesofSTTstorspecificchemicalclass.Forillustrativepmposesthecarclnogenicitypredictionofseveralsamplechamicalsispresented.Theresultsofcost-effectivenessanalysissuggestthatthisprogramhasvastsocial-economiceffectiveness.

简介：Objective:Hepatocellularcarcinoma(HCC)isacommonmalignancyassociatedwithhighmorbidityandmortalityratesworldwide.EarlydiagnosisplaysanimportantroleintheimprovementofHCCprognosis.Methods:Inthisstudy,weconductedacomprehensiveanalysisofHCCDNAmethylationandgeneexpressiondatasetsinTheCancerGenomeAtlas(TCGA),toidentifyaprognosticsignatureforHCCdiagnosisandsurvivalprediction.First,weidentifieddifferentialmethylationCpG(dmCpG)sitesinHCCsamplesandcomparedthemwiththoseinadjacentnormallivertissues;thiswasfollowedbyunivariateanalysisandSureIndependenceScreening(SIS)inthetrainingset.Therobustnessoftheidentifiedprognosticsignaturewasevaluatedusingthetestingset.ToexplorethebiologicalprocessesinvolvedinHCCprogression,wealsoperformedfunctionalenrichmentanalysisforoverlappinggenesbetweengenescontainingdmCpGsites(DMGs)anddifferentialexpressiongenes(DEGs)inHCCpatients,usingdatafromtheDatabaseforAnnotation,Visualization,andIntegratedDiscovery(DAVID).Results:Asaresult,weidentifiedfiveCpGsitesthatweresignificantlyassociatedwithHCCsurvivalthroughunivariateanalysisandSIS.Univariateanalysisofclinicalcharacteristicsidentifiedageandriskfactors(includingalcoholconsumptionandsmoking)asindependentfactorsthatindicatedHCCsurvival.Multivariateanalysisindicatedthattheintegratedprognosticsignature(weightedcombinationofthefiveCpGsites)thattookageandriskfactorsintoconsiderationresultedinmoreaccuratesurvivalprediction.Conclusions:ThisstudyprovidesanovelsignatureforpredictingHCCsurvival,andshouldbehelpfulforearlyHCCdiagnosisandpersonalizedtreatment.

简介：Objective:BethesdaSystemforReportingThyroidCytopathology(BSRTC)categoriesⅠ,Ⅲ,andⅤaccountforasignificantproportionoffineneedleaspirationcytology(FNAC)diagnoses.ThisstudyaimedtocomparethediagnosticefficacyofBRAFV600EmutationandtheThyroidImagingReportingandDataSystem(TIRADS)classificationindifferentiatingpapillarythyroidcancers(PTCs)frombenignlesionsamongBSRTCI,III,andVnodules.Methods:Atotalof472patientswith479noduleswereenrolledinthisprospectivestudy.Ultrasound,BRAFV600Emutationtesting,andFNACwereperformedineachnodule,followedbysurgeryorregularultrasoundexamination.Results:IntheBSRTCIcategory,BRAFV600Eshowedsimilarsensitivity,higherspecificity,andloweraccuracywhencomparedwithTIRADS.IntheBSRTCIII/Vcategory,thesensitivity,specificity,andaccuracyofBRAFV600EweresimilartothoseofTIRADS.IncomparisontoBRAFV600Ealone,thecombinationofthetwomethodssignificantlyimprovedsensitivity(BSRTCⅠ:93.6%vs.67.7%,P<0.01;BSRTCⅢ:93.8%vs.75.0%,P<0.01;BSRTCV:96.0%vs.85.3%,P<0.001).WhencomparedwithTIRADSalone,thecombinationimprovedsensitivityinBSRTCⅠnodules(93.6%vs.74.2%,P<0.05),increasedsensitivityanddecreasedaccuracyinBSRTCIIInodules(93.8%vs.75.0%,P<0.01,91.0%vs.93.6%,P<0.01),andimprovedbothsensitivityandaccuracyinBSRTCVnodules(96.0%vs.82.0%,P<0.001;94.2%vs.81.3%,P<0.001).Conclusions:BRAFV600EexhibitedhigherspecificityandloweraccuracycomparedwithTIRADSinBSRTCⅠnodules,whilethetwomethodsshowedsimilardiagnosticvalueinBSRTCⅢ/Ⅴnodules.ThecombinationofthetwomethodsdistinctlyimprovedsensitivityinthediagnosisofPTCsinBSRTCⅠ,Ⅲ,andⅤnodules.